Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-31

Clinical Trial Update: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update for TCD601 (Siplizumab) in newly diagnosed adult amyotrophic lateral sclerosis patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TCD601 (Siplizumab) (Siplizumab)

Snippet

Sponsor: ITB-Med LLC | Conditions: ALS | Phase 1 | Status: RECRUITING